A phase 3 randomised controlled trial in 954 patients with advanced HCC has compared lenvatinib versus sorafenib in first line. Overall survival was not different between lenvatinib (13.6 months) and sorafenib (12.3 months) meeting the primary endpoint of non-inferiority in term of overall survival.
Consequently, lenvatinib is a new option for the first-line treatment of advanced HCC.
(Kudo M et al. – The Lancet, 24 March 2018)